| Follow us on Twitter |
The past twelve months have illustrated that the transdermal segment has some work to do before it can achieve the commercial stature that has so far eluded it. Recent problems related to patch manufacturing quality have resulted in costly product recalls and interrupted the market momentum of promising patch products.
Several of the emerging drug products covered in this report have the potential to improve patient quality of life and in the process help transform transdermal therapeutics from a novelty to a mainstream healthcare technology. For transdermal drug developers and their supply chain partners, understanding the concerns, preferences, and limitations of targeted patient groups to self-medicate via traditional pain medication methods will be an important factor in successfully addressing this market segment.
Detailed analysis of transdermal pain management products, API’s, indications and participants is included in a comprehensive report. The report documents and analyzes the results of a recent survey of the pain drug delivery sector conducted by Applied Data Research.
More information is also available at www.applieddata.org .
About Applied Data
Applied Data Research is a healthcare therapeutics consulting firm focused on medical market strategies, product commercialization, venture development, and market research. We assist medical market participants in achieving their business objectives through the creation of detailed business development strategies, product commercialization programs, and comprehensive market and technology research and analysis.
Contact:
Greg Stone
Voice: 603-595-6225
www.applieddata.org
Source: Applied Data Research
Posted April 21st, 2009 by gstone
